当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Factors predicting in-breast tumor recurrence after breast-conserving surgery.

Factors predicting in-breast tumor recurrence after breast-conserving surgery.

Abstract：

PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treated with breast conserving therapy. Univariate and multivariate statistical analysis were performed and survival rates were calculated and analyzed using the Kaplan-Meier method. RESULTS:With a median follow-up period of 70.6 months 14 patients (4%) developed an IBTR. Overall survival and the disease-free 8-year actuarial survival of patients were 95% and 93%, respectively. The overall survival of patients with tumour recurrence on any site was significantly shorter than of those without recurrence (64% versus 85% after 8 years of follow-up; P < 0.0001). Similarly, overall survival was significantly reduced in patients with distant metastases compared to all others without distant disease (88% versus 40% after 8 years; P < 0.0001). In contrast, overall survival of patients who experienced IBTR did not differ significantly from the group of patients who never developed IBTR (87% versus 70% after 8 years of follow-up). By univariate analysis, lobular carcinoma, high grade tumours, multifocality, concomitant LCIS and DCIS, the absence of estrogene and progesterone receptor status, as well as R1-status, were significant predictors of IBTR. By multivariate analysis, only R1-status (P < 0.002) and the presence of LCIS around the invasive tumour (P < 0.03) remained as significant factors predicting IBTR. CONCLUSIONS:Concomitant lobular carcinomas in situ, as well as R1 surgical status are independent significant risk factors for in breast tumor recurrence after breast conserving therapy.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Mechera R,Viehl CT,Oertli D

doi

10.1007/s10549-008-0187-y

subject

Has Abstract

pub_date

2009-07-01 00:00:00

pages

171-7

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

116

pub_type

临床试验,杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.

    abstract：PURPOSE:Vitamin D (VD) metabolism regulates adipose tissue, lipogenesis inflammation, and tumor growth. CYP24A1 is the key enzyme for metabolic inactivation of active VD (1,25(OH)2D3). We examined whether common germline single nucleotide polymorphisms (SNPs) in the CYP24A1 gene could affect the association between adu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05484-6

    authors： Cao S,Wei F,Zhou J,Zhu Z,Li W,Wu M

    更新日期：2020-01-01 00:00:00

  • Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.

    abstract：:Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-016-3876-y

    authors： Veeraraghavan J,Ma J,Hu Y,Wang XS

    更新日期：2016-07-01 00:00:00

  • Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls.

    abstract：:The association of CYP19 gene polymorphisms with breast cancer has been widely reported, but results of previous studies were somewhat contradictory and underpowered. In order to overcome the limitations of individual study and to understand the real situation, we conducted a systematic review and meta-analysis includ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-009-0693-6

    authors： Ma X,Qi X,Chen C,Lin H,Xiong H,Li Y,Jiang J

    更新日期：2010-07-01 00:00:00

  • Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.

    abstract：:It is still controversial whether the identification of micrometastases and isolated tumor cells in the axillary lymph nodes of patients with breast cancer has any prognostic value. We evaluated the prognostic role of isolated tumor cells and micrometastases in the axillary lymph nodes in 3,158 consecutive patients pT...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0446-6

    authors： Montagna E,Viale G,Rotmensz N,Maisonneuve P,Galimberti V,Luini A,Intra M,Veronesi P,Mazzarol G,Pruneri G,Renne G,Torrisi R,Cardillo A,Cancello G,Goldhirsch A,Colleoni M

    更新日期：2009-11-01 00:00:00

  • Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

    abstract：PURPOSE:To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-008-0055-9

    authors： Dickler MN,Cobleigh MA,Miller KD,Klein PM,Winer EP

    更新日期：2009-05-01 00:00:00

  • Hormones and hormone receptors in the etiology of breast cancer.

    abstract：:Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：

    authors： Thomas DB

    更新日期：1986-01-01 00:00:00

  • Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

    abstract：:Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot co...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10549-011-1612-1

    authors： Hadad S,Iwamoto T,Jordan L,Purdie C,Bray S,Baker L,Jellema G,Deharo S,Hardie DG,Pusztai L,Moulder-Thompson S,Dewar JA,Thompson AM

    更新日期：2011-08-01 00:00:00

  • Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.

    abstract：:Taxanes are being used for the treatment of breast cancer. However, cancer cells frequently develop resistance to these drugs with the subsequent recurrence of the tumor. MDA-MB-231 and T-47D breast cancer cell lines were used to assess the effect of paclitaxel treatment on apoptosis and cell cycle, the possible mecha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1864-9

    authors： Flores ML,Castilla C,Ávila R,Ruiz-Borrego M,Sáez C,Japón MA

    更新日期：2012-06-01 00:00:00

  • Delayed versus immediate exercises following surgery for breast cancer: a systematic review.

    abstract：BACKGROUND:Seroma formation, wound healing and fluid drainage are a concern for both surgeons and patients. Excessive fluid production can result in seroma formation, and inadequate drainage of seromas is known to cause infection, pain, discomfort and longer periods of hospitalisation. Postoperative exercises given to ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-004-4727-9

    authors： Shamley DR,Barker K,Simonite V,Beardshaw A

    更新日期：2005-04-01 00:00:00

  • Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.

    abstract：:Compelling evidence about the differences in the biology and behavior of invasive breast cancer between African-American (AA) and White-American (WA) women motivate inquiry into comparing the clinicopathology of non-invasive breast cancer (ductal carcinoma in situ, DCIS). AA and WA women diagnosed with their first pri...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1742-5

    authors： Stark A,Stapp R,Raghunathan A,Yan X,Kirchner HL,Griggs J,Newman L,Chitale D,Dick A

    更新日期：2012-01-01 00:00:00

  • Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.

    abstract：PURPOSE:The separate impacts of dose and dose intensity of chemotherapy for metastatic breast cancer remain uncertain. The primary objective of this trial was to compare a short, high-dose, intensive course of epirubicin and cyclophosphamide (EC) with a longer conventional dose regimen delivering the same total dose of...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-019-05187-y

    authors： Ackland SP,Gebski V,Zdenkowski N,Wilson A,Green M,Tees S,Dhillon H,Van Hazel G,Levi J,Simes RJ,Forbes JF,Coates AS,for Breast Cancer Trials Ltd (formerly known as the Australia and New Zealand Breast Cancer Trials Group).

    更新日期：2019-07-01 00:00:00

  • Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.

    abstract：:Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2113-6

    authors： Taghipour S,Banjevic D,Fernandes J,Miller AB,Montgomery N,Harvey BJ,Jardine AK

    更新日期：2012-07-01 00:00:00

  • The influence of angiogenesis research on management of patients with breast cancer.

    abstract：:The diagnosis and treatment of patients with breast cancer is beginning to be influenced by new ideas and discoveries emerging from the field of angiogenesis research. This field, pursued in the laboratory for more than 20 years, has in the past 5 years generated clinical applications. Some of these applications have ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666033

    authors： Folkman J

    更新日期：1995-01-01 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract：:Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01807591

    authors： Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期：1983-01-01 00:00:00

  • Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.

    abstract：:Considerable effort has been placed into the identification of new antineoplastic agents to treat breast cancer and other malignant diseases. The basic approaches, in terms of model selection, endpoints, and data analysis, have changed in the previous few decades. This article deals with many of the issues associated ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1005938428456

    authors： Clarke R

    更新日期：1997-11-01 00:00:00

  • Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.

    abstract：:We describe a method for the isolation of free DNA from ductal lavage (DL) and nipple aspirate fluid (NAF), and its evaluation for the presence of LOH at the BRCA1 and FHIT genes and for mitochondrial DNA (mtDNA) mutations at the D310 marker, to improve early detection of breast cancer. We evaluated 26 DL and six NAF ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000018406.03679.2e

    authors： Isaacs C,Cavalli LR,Cohen Y,Pennanen M,Shankar LK,Freedman M,Singh B,Liu M,Gallagher A,Rone JD,Dickson RB,Sidransky D,Haddad BR

    更新日期：2004-03-01 00:00:00

  • Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?

    abstract：PURPOSE:The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician's decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralatera...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4426-y

    authors： Jonna AR,Sam KQ,Ebuoma LO,Sedgwick EL,Wang T,Benveniste AP

    更新日期：2017-11-01 00:00:00

  • Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

    abstract：PURPOSE:We conducted an exploratory biomarker study from a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in HER2-negative metastatic breast cancer (BC) patients. METHODS:We performed targeted deep sequencing with a customized cancer gene panel and RNA expression assa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05400-y

    authors： Kim JY,Lee E,Park K,Im SA,Sohn J,Lee KS,Chae YS,Kim JH,Kim TY,Jung KH,Park YH,Breast Cancer Committee of the Korean Cancer Study Group.

    更新日期：2019-11-01 00:00:00

  • The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.

    abstract：PURPOSE:To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy. METHODS:A retrospective search of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy at the Roy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0081-7

    authors： Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期：2009-07-01 00:00:00

  • Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

    abstract：:The effect of 17-beta-estradiol (E2) on the induction of osteolytic lesions by estrogen receptor (ER)-negative breast cancer cells was investigated in 4-week-old female nude mice. Exposure to exogenous E2 was found to increase osteolytic areas on radiographs up to 5.3 times in mice inoculated intracardially with MDA-2...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1022943127689

    authors： Winding B,Misander H,Høegh-Andersen P,Brünner N,Foged NT

    更新日期：2003-03-01 00:00:00

  • Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.

    abstract：BACKGROUND:Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast...

    journal_title：Breast cancer research and treatment

    pub_type： 社论,多中心研究

    doi：10.1007/s10549-018-4825-8

    authors： O'Loughlin M,Andreu X,Bianchi S,Chemielik E,Cordoba A,Cserni G,Figueiredo P,Floris G,Foschini MP,Heikkilä P,Kulka J,Liepniece-Karele I,Regitnig P,Reiner A,Ryska A,Sapino A,Shalaby A,Stovgaard ES,Quinn C,Walsh EM,Z

    更新日期：2018-08-01 00:00:00

  • Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

    abstract：AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1010669403283

    authors： Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

    更新日期：2001-04-01 00:00:00

  • Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.

    abstract：:Cell-mediated immune (CMI) responses to tumor-associated antigens (TAA) in the early postoperative period were examined for correlations with disease recurrence and survival in a 13-year-prospective study of 77 stage 1 and 2 breast cancer patients treated with modified radical or radical mastectomy alone. Among the 21...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006405504158

    authors： Mccoy JL,Rucker R,Petros JA

    更新日期：2000-04-01 00:00:00

  • Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.

    abstract：PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4037-z

    authors： Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

    更新日期：2017-01-01 00:00:00

  • Evaluating breast cancer risk projections for Hispanic women.

    abstract：:For Hispanic women, the Breast Cancer Risk Assessment Tool (BCRAT; "Gail Model") combines 1990-1996 breast cancer incidence for Hispanic women with relative risks for breast cancer risk factors from non-Hispanic white (NHW) women. BCRAT risk projections have never been comprehensively evaluated for Hispanic women. We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1900-9

    authors： Banegas MP,Gail MH,LaCroix A,Thompson B,Martinez ME,Wactawski-Wende J,John EM,Hubbell FA,Yasmeen S,Katki HA

    更新日期：2012-02-01 00:00:00

  • The effects of TGF-alpha and 17 beta-estradiol on polyphosphoinositide metabolism in MCF-7 breast cancer cells.

    abstract：:The mechanism by which transforming growth factor-alpha (TGF-alpha) stimulates breast cancer cell proliferation is largely unknown. Furthermore, its potential role as an autocrine effector of estradiol-17 beta (E2)-stimulated growth of hormone-dependent mammary tumors remains controversial. Transient changes in phosph...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01832359

    authors： Etindi RN,Manni A,Martel J

    更新日期：1992-01-01 00:00:00

  • Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue.

    abstract：:Breast cancer is one of the most common cancers in women. The laboratory rat treated with strong carcinogen is the most commonly used animal model for study of breast cancer. Transgenic mouse lines with homologues of human breast cancer oncogenes have been developed. The transgenic mouse line TG.NK with c-neu, the hum...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005822318256

    authors： Rao GN,Ney E,Herbert RA

    更新日期：1997-09-01 00:00:00

  • Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.

    abstract：:Mammographic density is a strong and independent risk factor for breast cancer and is considered an intermediate marker of risk. The major predictors of premenopausal mammographic density, however, have yet to be fully elucidated. To test the hypothesis that urinary estrogen metabolism profiles are associated with mam...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2240-0

    authors： Bertrand KA,Eliassen AH,Hankinson SE,Gierach GL,Xu X,Rosner B,Ziegler RG,Tamimi RM

    更新日期：2012-11-01 00:00:00

  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

    abstract：PURPOSE:Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies. METHODS:cHER2 status was determined in 105 advanced-stage patient...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05662-x

    authors： Wang C,Mu Z,Ye Z,Zhang Z,Abu-Khalaf MM,Silver DP,Palazzo JP,Jagannathan G,Fellin FM,Bhattacharya S,Jaslow RJ,Tsangaris TN,Berger A,Neupane M,Cescon TP,Lopez A,Yao K,Chong W,Lu B,Myers RE,Hou L,Wei Q,Li B,Cri

    更新日期：2020-06-01 00:00:00

  • Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

    abstract：:Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period cha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0615-7

    authors： Lambe M,Wigertz A,Holmqvist M,Adolfsson J,Bardage C,Fornander T,Karlsson P,Odlind V,Persson I,Ahlgren J,Bergkvist L

    更新日期：2010-06-01 00:00:00